(secondQuint)An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects.

 This protocol is designed to test the safety and efficacy of a drug called beloranib (ZGN-440 for injectable suspension).

 It is to be tested for its ability to reduce weight in obese subjects.

 The study will provide information on how much ZGN-440 gets into the blood, how long it stays in the body, and how it affects other biological markers.

.

 An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects@highlight

The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.

